+

WO1999015159A3 - Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives - Google Patents

Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives Download PDF

Info

Publication number
WO1999015159A3
WO1999015159A3 PCT/IB1998/001679 IB9801679W WO9915159A3 WO 1999015159 A3 WO1999015159 A3 WO 1999015159A3 IB 9801679 W IB9801679 W IB 9801679W WO 9915159 A3 WO9915159 A3 WO 9915159A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disease
treatment
methods
apoe levels
increasing apoe
Prior art date
Application number
PCT/IB1998/001679
Other languages
English (en)
Other versions
WO1999015159A2 (fr
Inventor
Judes Poirier
Original Assignee
Nova Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Molecular Inc filed Critical Nova Molecular Inc
Priority to CA002304505A priority Critical patent/CA2304505A1/fr
Priority to EP98947709A priority patent/EP1017375A2/fr
Priority to AU94540/98A priority patent/AU9454098A/en
Priority to JP2000512529A priority patent/JP2001517617A/ja
Publication of WO1999015159A2 publication Critical patent/WO1999015159A2/fr
Publication of WO1999015159A3 publication Critical patent/WO1999015159A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une méthode permettant de ralentir l'évolution d'une maladie neurodégénérative chez des patients en leur administrant des doses thérapeutiquement efficaces d'un composé pouvant augmenter les taux d'ApoE (apolipoprotéine).
PCT/IB1998/001679 1997-09-24 1998-09-24 Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives WO1999015159A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002304505A CA2304505A1 (fr) 1997-09-24 1998-09-24 Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
EP98947709A EP1017375A2 (fr) 1997-09-24 1998-09-24 Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
AU94540/98A AU9454098A (en) 1997-09-24 1998-09-24 Methods for increasing apoe levels for the treatment of neurodegenerative disease
JP2000512529A JP2001517617A (ja) 1997-09-24 1998-09-24 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5990897P 1997-09-24 1997-09-24
US60/059,908 1997-09-24

Publications (2)

Publication Number Publication Date
WO1999015159A2 WO1999015159A2 (fr) 1999-04-01
WO1999015159A3 true WO1999015159A3 (fr) 2000-02-17

Family

ID=22026067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001679 WO1999015159A2 (fr) 1997-09-24 1998-09-24 Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives

Country Status (6)

Country Link
US (2) US6274603B1 (fr)
EP (1) EP1017375A2 (fr)
JP (1) JP2001517617A (fr)
AU (1) AU9454098A (fr)
CA (1) CA2304505A1 (fr)
WO (1) WO1999015159A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29158A (id) 1997-05-14 2001-08-02 Atherogenics Inc Monoester probukol untuk pengobatan penyakit kardiovaskular dan peradangan
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US8679534B2 (en) 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US7223428B2 (en) * 1998-01-09 2007-05-29 Mars Incorporated Method of embossing chocolate products
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6440678B1 (en) * 1998-08-28 2002-08-27 Board Of Trustees Of University Of Arkansas Materials and methods related to the inflammatory effects of secreted amyloid precursor proteins
JP2002526124A (ja) 1998-10-01 2002-08-20 ノヴァ モレキュラー インク． 変異型ｇｐｉｉｉａ対立遺伝子および／または変異型ｇｐｉｉｂ対立遺伝子の存在を決定することにより、神経系疾患のリスクを有する対象を治療又は同定する方法
EP2133078A1 (fr) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Utilisation d'un inhibiteur de la cholinestérase pour le traitement de troubles cognitifs et/ou d'une démence associés à ou provoqués par des tumeurs cérébrales
WO2001072307A1 (fr) * 2000-03-29 2001-10-04 The J. David Gladstone Institutes Procedes de traitement de declins cognitifs au moyen d'androgenes
EP1370210A4 (fr) * 2001-02-07 2004-08-18 Mclean Hospital Corp Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
WO2003086379A1 (fr) * 2002-04-12 2003-10-23 Henry Ford Health System Traitement de lesions neuronales et de maladies neurodegeneratives par des statines
NZ560368A (en) * 2002-05-03 2008-11-28 Israel Inst Biolog Res Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2004110357A2 (fr) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Composes heterocycliques et leurs utilisations
JP5133561B2 (ja) * 2003-06-19 2013-01-30 メルク セローノ ソシエテ アノニム プリオン変換を調節する因子の使用
WO2005087226A1 (fr) * 2004-03-05 2005-09-22 Eisai Co., Ltd. Traitement de cadasil avec des inhibiteurs de la cholinesterase
CA2566373A1 (fr) * 2004-05-27 2005-12-08 Migenix Corp. Composes et methodes de cytoprotection
JPWO2006004201A1 (ja) * 2004-07-01 2008-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経再生促進剤
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
EP2801366A3 (fr) * 2004-09-02 2015-04-29 Cognosci, Inc. Analogues apo E améliorés et leurs procédés d'utilisation
WO2007014219A2 (fr) * 2005-07-25 2007-02-01 The Curavita Corporation Mesure de la dynamique d'une demarche et utilisation de betabloquants pour detecter, pour pronostiquer, pour eviter et pour traiter une sclerose laterale amyotrophique
KR101591223B1 (ko) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
EP1801098A1 (fr) * 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
CA2657681C (fr) * 2006-07-14 2019-03-19 Ac Immune S.A. Anticorps humanises contre la proteine beta-amyloide
AU2008230861A1 (en) 2007-03-26 2008-10-02 Salutria Pharmaceuticals, Llc Methods and compositions of derivatives of probucol for the treatment of diabetes
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101883791B (zh) * 2007-10-05 2015-11-25 基因技术公司 人源化抗体
CA2701793C (fr) 2007-10-05 2017-04-25 Genentech, Inc. Utilisation d'anticorps beta anti-amyloides contre les maladies occulaires
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
EP2211911A4 (fr) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc Procédés de diagnostic et de surveillance du traitement de la démence à corps de lewy par évaluation des niveaux de transporteur de la dopamine
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
EP2598882B1 (fr) 2010-07-30 2017-07-26 AC Immune S.A. Anticorps humanisés sûrs et fonctionnels pour utilisation dans le traitement de l'amyloïdose
CN109942714B (zh) * 2019-04-02 2022-07-08 中国药科大学 一种功能多肽及应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296560A2 (fr) * 1987-06-22 1988-12-28 Eisai Co., Ltd. Pipéridines 1,4-substituées comme inhibiteurs de l'acétylcholinestérase et leur utilisation dans le traitement de la maladie d'Alzheimer
WO1995001096A1 (fr) * 1993-06-29 1995-01-12 Shapiro Howard K Compositions pharmaceutiques et leur utilisation pour le traitement d'affections neurologiques et de symptomologies a etiologies associees
WO1995006470A1 (fr) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention et traitement de la maladie d'alzheimer
WO1995029257A2 (fr) * 1994-04-27 1995-11-02 Mcgill University Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer
WO1997038694A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
WO1997046526A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes stables d'hydrochlorure de 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-piperidine), dit hydrochlorure de donepezil et procede pour leur production
WO1998031366A1 (fr) * 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol
WO1998051289A2 (fr) * 1997-05-14 1998-11-19 Atherogenics, Inc. Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1199076B (it) * 1984-03-01 1988-12-30 Consiglio Nazionale Ricerche Derivati della fisostigmina con proprieta'di inibizione della aceticolinesterasi e relativo procedimento di produzione
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
AU5317296A (en) 1995-03-24 1996-10-16 Francis V. Defeudis Methods for treating conditions associated with excess nitri c oxide
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296560A2 (fr) * 1987-06-22 1988-12-28 Eisai Co., Ltd. Pipéridines 1,4-substituées comme inhibiteurs de l'acétylcholinestérase et leur utilisation dans le traitement de la maladie d'Alzheimer
WO1995001096A1 (fr) * 1993-06-29 1995-01-12 Shapiro Howard K Compositions pharmaceutiques et leur utilisation pour le traitement d'affections neurologiques et de symptomologies a etiologies associees
WO1995006470A1 (fr) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention et traitement de la maladie d'alzheimer
WO1995029257A2 (fr) * 1994-04-27 1995-11-02 Mcgill University Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer
WO1997038694A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
WO1997046526A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes stables d'hydrochlorure de 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-piperidine), dit hydrochlorure de donepezil et procede pour leur production
WO1998031366A1 (fr) * 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Methode de traitement de l'atherosclerose a l'aide d'un inhibiteur de mpt et de medicaments reduisant le cholesterol
WO1998051289A2 (fr) * 1997-05-14 1998-11-19 Atherogenics, Inc. Monoesters de probucol destines au traitement de troubles cardio-vasculaires et inflammatoires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABURATANI, HIROYUKI ET AL: "Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of probucol -treated rabbits", AM. J. CARDIOL. (1988), 62(3), 60B-65B CODEN: AJCDAG;ISSN: 0002-9149, XP002104837 *
KALRA S. ET AL: "Lewy body disease and dementia: A review.", ARCHIVES OF INTERNAL MEDICINE, (1996) 156/5 (487-493). ISSN: 0003-9926 CODEN: AIMDAP, United States, XP002104836 *
MIETTINEN T A ET AL: "Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality.", JAMA, (1985 OCT 18) 254 (15) 2097-102. JOURNAL CODE: KFR. ISSN: 0098-7484., United States, XP002104832 *
NAITO, MICHITAKA (1) ET AL: "Protective effects of probucol against glutamate-induced cytotoxicity in neuronal cell line PC12.", NEUROSCIENCE LETTERS, (1995) VOL. 186, NO. 2-3, PP. 211-213. ISSN: 0304-3940., XP002104834 *
PIKE, CHRISTIAN J. ET AL: ".beta.-amyloid neurotoxicity in vitro: evidence of oxidative stress but not protection by antioxidants", J. NEUROCHEM. (1997), 69(4), 1601-1611 CODEN: JONRA9;ISSN: 0022-3042, XP002104831 *
SOININEN, HILKKA S. ET AL: "Apolipoprotein E, memory and Alzheimer's disease", TRENDS NEUROSCI. (1996), 19(6), 224-228 CODEN: TNSCDR;ISSN: 0166-2236, XP002104835 *
STEIN U.: "Free radicals and antioxidants.", REVISTA BRASILEIRA DE NEUROLOGIA, (1994) 30/SUPPL. 1 (12S-17S). ISSN: 0101-8469 CODEN: RBNEE5, Brazil, XP002104833 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Also Published As

Publication number Publication date
CA2304505A1 (fr) 1999-04-01
JP2001517617A (ja) 2001-10-09
WO1999015159A2 (fr) 1999-04-01
US20010051602A1 (en) 2001-12-13
EP1017375A2 (fr) 2000-07-12
AU9454098A (en) 1999-04-12
US6274603B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
WO1999015159A3 (fr) Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
WO1999022721A3 (fr) Procede de traitement de l'hypercholesterolemie a l'aide de polydiallylamine non substituee
CA2180535A1 (fr) Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
AU2001251546A1 (en) Method for treating pain by peripheral administration of a neurotoxin
CA2370030A1 (fr) Composition de blocage du canal sodique et leur utilisation
AU6586896A (en) Fatty acid treatment
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
EP1029540A3 (fr) Utilisation de la droloxifène pour le traitement de maladies cardiovasculaires
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
HK1029942A1 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma.
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
ZA995444B (en) A method for the treatment of staphylococcal disease.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
AU5733099A (en) Method for treating ocular neovascular diseases
AU2001283504A1 (en) Cell implantation therapy for neurological diseases or disorders
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
WO2002043715A3 (fr) Utilisation de composes 1-phenyl-3-dimethylamino-propane pour traiter l'incontinence urinaire
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AU6369396A (en) Drug for ameliorating brain diseases
WO2002043714A3 (fr) Utilisation de composes 6-dimethylaminomethyle-1-phenyl-cyclohexane substitues pour traiter l'incontinence urinaire
WO2000010544A3 (fr) Procede prevenant l'apparition de l'asthme
HK1044279A1 (en) Aminotetralin derivative for the therapy of cardiovascular diseases
ZA200204204B (en) Method for producing therapeutic agents for ulcers.
AU6097394A (en) Method for the treatment of respiratory disease
AU6896198A (en) Method for treating cerebral focal stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP MX NZ SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2304505

Country of ref document: CA

Ref country code: CA

Ref document number: 2304505

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 94540/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998947709

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998947709

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998947709

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载